PharmaTelevision - The Future

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: The Future

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

The Future

Paul Larsmon reviews a series of interviews with some of Pharma and Biotech’s biggest players, including Doug Giordano from Pfizer, Dan Zabrowski from Roche and Jean-Claude Muller from Sanofi-Aventis. In this programme we look forward to 2010 and beyond within the industry and see what predictions will be made for its future.

Changes in future biopharma.

Paul Larsmon:

Hello I am Paul Larsmon, it's December the 31st 2009. Welcome to PharmaTelevision news. We are taking advantage of the holiday period to run a series of special programs in which leading industry figures reflect on the year that's passed and look forward to the one that's to come. So after a year of change enforced by the financial crisis and biopharma's very own challenges what does the future hold, change it seems and more change?

Steve Parkinson:

Well you know after the sort of events of 9/11 we thought you know we never gonna see investment again in anything and of course it did come back. And so I think even in this terrible economic cycle it will come back, so question of when, ultimately the money is going to drive it. I mean you know people are going to be looking for bigger returns on money you know that you're not getting the return on now your money in the bank at the moment. So you know I think it will drive it, but it's just a question of when, it's going to take time.

Mervyn Turner:

The pharma sector will undoubtedly go through massive changes over the next 5 to 10-years with the patent cliffs coming, the regulatory environment, the payer environment, healthcare reimbursement. This echo system is gonna go through some, some wrenching changes and we will all have to attempt, big pharma, biotech, venture will all gonna have to find different ways of working together I believe.

Relationships with biotech.

Paul Larsmon:

Adapting and working together differently at BIO-Europe a couple of months ago I spoke to some of big pharma's biggest hitters, so what did they see in their crystal ball and what it will mean for relations with biotech?

Dan Zabrowski:

You will still see the number of biotech companies reduced. I do think you will see more large pharma collaborations. I do think you're gonna see more pharma, large pharma get involved in early stage research programs and try to form partnerships with biotech's and the venture capital investors sooner than later.

Doug Giordano:

This industry is founded on symbiotic partnership relationship between the biotech community whether that's in Europe or in the United States or in Asia and a larger you know pharmaceutical infrastructure companies. And you know from our perspective if Pfizer as a larger player with a large sales and marketing infrastructure is going to continue to achieve what it needs to achieve not only in the short-term then in the longer-term, we were gonna need a very healthy and viable biotech community.

Gino Santini:

Priority number one for us at least that Eli Lilly is " how do we fill the pipeline. The pipeline right now has some gaps. And if you want to continue to enjoy the growth in the future that is consistent with our, our expected on a long range plan, but we need more molecules. So this is the good news for the biotech in the audience that have new innovative molecules that have good value. We are really hungry for those, so whether it is through licensing deals or changing control we are really scouting the environment and we are really looking for, for those molecules to bring in.

Sanofi-Aventis's vision for future.

Paul Larsmon:

With a new chief exec and a new vision Sanofi-Aventis is also been looking at new ways of doing things.

Jean-Claude Muller:

What we will need it for the future is to build new type of alliances and when you know you had all the partnership or the in-licensing or the acquisition, I do believe there are other ways to do things. In a way whereby one would assist let's say raise funding at the proper time but where the smaller company would run the whole let's say discovery and early phase things well we will just assist them and then see what is the best possible way. So we will not become a venture capital company that we expect some of our partners have become, so I don't think that's really what we want to do. Think we wanna want to have a full risk sharing with them so that they have access to the funding's they need to get things done, but where they would be independent enough to be able to have as I said earlier this agility to move around to be a biotech company in that respect and then come with deliverables and then you know once you have the deliverables to develop then it's usually different game and that's where my we should take the lead in those respects. So I would say we have to build new alliances to be smart and see with the partner how to share the best possible ways to do so.

Optimism in biotech sector.

Paul Larsmon:

Well despite the difficult times there is still a huge amount of optimism in our sector and the feeling may be what doesn't kill makes you stronger?

Paul J. Hastings:

I think there are no guarantees and that just a way our industry works and so one has to operate. And the mode of knowing that what one might expect to happen may not.

Steve Parkinson:

I think we are gonna see companies merging together, we'll probably see a lot of M&A activity I think in the next year or two, but hopefully you know the money will come back to the innovation, because in the end I think this is still the most dynamic field probably the most active field you know going forward.

Paul Larsmon:

Well it just remains from me to wish you all a very happy and prosperous 2010. We will back with PharmaTelevision news on Monday January the 4th your news, your views, your channel. Goodbye.

Paul J. Hastings

President and CEO

Doug Giordano, VP, Business Development at Pfizer Past: Consultant at boos Allen & Hamilton Education: Cornell University - S.C. Johnson Graduate School of Management Duke University. Dan Zabrowski has been the Head of Pharma Partnering since July 2007. His team is dedicated to finding the best external innovation to strengthen the Roche R&D portfolio. Jean-Claude Muller started his career in 1974 as an organic chemist at Roche at Basle Switzerland. He moved to Nutley USA in 1979. In 1983, he joined Synthelabo, Paris France where he leaded the cardiovascular research organization for several years prior to becoming in 1994 a corporate manager in charge of external projects and research alliances at Synthelabo was a deal architect in the genomic alliances with Human Genome Sciences, Inc.USA and GensetFrance and the acquisition of the Strasbourg Research facility from Hoechst Marion Roussel. In 1992, he was the Strategic Corporate Manager Responsible for the Assessment of External Opportunities, the Identification and Implementation of R&D Alliances and the Competitive Intelligence Surveys. In 2003, he became Vice-President Administration & Resources. He was in charge of the integration between Sanofi and Aventis, of managing the resources and budget of sanofi-aventis R&D and in charge of Instrumental in the alliance building with Regeneron. Since November 2008, he is a Current Senior Vice President Prospective & Strategic Initiatives he is in charge of constructing R&D 2015 Steve Parkinson, President and CEO at Lakewood-Amedex, has over 25 years experience in the biopharmaceutical industry, including four CEO roles over the last eleven years, one of them as founder and CEO of TranXenoGen, a company he took public on London AIM. As President and CEO of CereMedix, a drug discovery and development company, he advanced their first product to clinical trials. Previously he was with Advanced Cell Technolog, Johnson & Johnson, PPL Therapeutics (Dolly the Sheep) and Genzyme Transgenics. Born and raised in Scotland he has lived and worked in the US for the past 20 years. Dr. Mervyn J. Turner is chief strategy officer for Merck & Co., Inc. and senior vice president, Worldwide Licensing and External Research, for Merck Research Laboratories. Since joining Merck in 1985, Dr. Turnerhas held many positions of increasing responsibility. Through his multiple an diverse experiences in the Merck Research Laboratories he has acquired a broad perspective on the issues surrounding drug discovery and development. Most recently (November 2008), Dr. Turnerwas appointed chief strategy officer for the Company. In this role, he reports to Richard T. Clark, chief executive officer, and has primary responsibility for partnering with Merck 's Executive Committee and leading the formulation and execution of Merck 's long term strategic plan. His role focuses on ensuring alignment of enterprise strategy with the business plans of Franchises, Divisions, and Functions. In August 1999, Dr. Turnerwas appointed senior vice president, Merck Frosst Centre for Therapeutic Research in Montreal, Canada. Dr. Turnerreturned from his assignment in Montreal in October 2002 to take up his position as senior vice president, Worldwide Licensing and External Research. In this role, he is responsible for the oversight of all of Merck 's licensing activities, and for the management of academic relations. During 2004 through 2006 there was a sizeable increase in deal activity for Merck , with more than 140 transactions completed. Merck has also been active in mergers and acquisitions, with Aton, Abmaxis, GlycoFi, and Sirna all acquired to build areas of key strategic importance. Dr. Turnersees all this activity as a logical product of a cultural shift within Merck toward a more outward-facing organization. Dr. Turneris the author of more than 80 articles in peer reviewed journals. He has served on the editorial board of a number of journals, and since 1998 has been a member of Health Care Ventures Scientific Advisory Board. Gino Santini was named senior vice president of corporate strategy and business development in June 2007. He is a member of the company's executive committee and is also a member of the senior management council. Santiniwas born in Cesena, Italy. He received a degree in mechanical engineering from the University of Bologna , Italy, in 1981 and a master of business administration degree from the University of Rochester in 1983. He joined Eli Lilly in 1983 as a financial planning associate in Italy and has held various positions in the financial and marketing components in Italy and Indianapolis. In 1990, Santini was appointed pharmaceutical director for the Eli Lilly affiliate in Belgium, and in 1991, he was named general manager of Eli Lilly Compania de Mexico in Mexico City. He served as area director of Latin America from 1994 to 1995. In 1995, he became vice president of corporate strategy and business development with the responsibility for the public policy and development group added in early 1996. He was named president of the women's health business unit in 1997. In 1999, he became president of U.S. operations. Santini is a past chairman of the board of the National Pharmaceutical Council. In addition, he serves on the executive board of Noble of Indiana, a nonprofit agency serving individuals with developmental disabilities in Central Indiana where he also served as board chairman. Mr. Santiniwas recently named the 2009 campaign chairman for United Way of Central Indiana. He will also serve on the board of directors for United Way. Mr. Hastingsbrings more than 20 years of experience as a biotechnology and pharmaceutical industry executive. He has served as President and CEO of OncoMed Pharmaceuticals since January 2006. Prior to joining OncoMed, Mr. Hastingswas President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastingsserved as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastingsalso held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President of Worldwide Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche. Mr. Hastingscurrently serves as Chairman of the Board of Directors of Proteolix, and also serves on the board of directors of Cerimon Pharmaceuticals. He received a Bachelor of Science degree in pharmacy from the University of Rhode Island.

Pfizer

PfizerGood health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them. We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer's disease and cancer. To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care. Roche plays a pioneering role in healthcare. As an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, Roche contributes on a broad range of fronts to improving people's health and quality of life. Roche is providing the first products that are tailored to the needs of specific patient groups. Their mission today and tomorrow is to create added value in healthcare by focusing on our expertise in diagnostics and pharmaceuticals. Roche is the world leader in in-vitro diagnostics and drugs for cancer, transplantation, and active in other major therapeutic areas with a high medical need such as autoimmune diseases, inflammatory diseases, virology, metabolic disorders and diseases of the central nervous system. Sanofi-AventisSanofi-Aventis (Euronext: SAN, NYSE: SNY), headquartered in Paris, France, is a multinational pharmaceutical company, the world's third-largest by prescription sales. Sanofi-Aventis engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Sanofi-Aventis covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines it is the world's largest producer of the latter through it's subsidiary Sanofi PasteurThe company is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Lakewood-AmedexLakewood-Amedex, a private development stage biopharmaceutical company, headquartered in Sarasota, Florida, has a diverse portfolio of targeted therapeutics, broad spectrum anti-bacterials, and anti-viral technologies. The lead product, LPI007, is a fully human toxin-neutralizing monoclonal antibody shown to be effective in the treatment of hemolytic uremic syndrome (HUS) caused by pathogenic Ecoli O157:H7 and will be entering Phase I clinical trials in late 2008. Nubiotics are a broad spectrum first in class group of anti-bacterial compounds that represent a first line defense against the increasing number of antibiotic resistant bacteria. A proprietary nanoRNA technology developed for the treatment of viral diseases, such as avian influenza and hepatitis. Merck & Co., Inc.Merck & Co., Inc.. is a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of products to improve human and animal health. Established in 1891, the Company%27s operations are principally managed on a products basis and comprises of two business segments: the Pharmaceutical segment and the Vaccines segment. The Pharmaceutical segment includes human health pharmaceutical products marketed either directly or through joint ventures. Merck sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Vaccines segment includes human health vaccines products marketed either directly or through a joint venture. These products consist of preventative pediatric, adolescent and adult vaccines, primarily administered at physician offices. Eli LillyWe were founded by Eli Lilly in 1876, and are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Eli Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Eli Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Eli Lilly employees have sustained a culture that values excellence, integrity, and respect for people. OncoMed PharmaceuticalsOncoMed Pharmaceuticals was founded in August 2004, by Drs. Michael F. Clarke and Max Wicha who led the discovery of cancerVaccinesstem cells, in solid tumorsVaccines. The ability to isolate and monitor tumorVaccines initiating cells using specific surface markers and flow cytometry has allowed OncoMed Pharmaceuticals to carefully evaluate the importance of specific targets associated with key biologic pathways implicated in both p stem cell biology and cancer. Antibodies against these targets have been developed and tested within xenograft models derived from freshly resected human cancers. Using these approaches, OncoMed has a portfolio of active antibodies that target biologic pathways critical for survival of tumor initiating cells. OncoMed's first antibody targeting the pathways critical to cancerstem cells has now entered clinical trials. Details of the initial Phase I study, which is now recruiting patients, may be found at ClinicalTrials.gov. Multiple additional promising therapeutic candidates that target other critical pathways are also being developed. OncoMed Pharmaceuticals has attracted significant funding from a prominent group of investors, that include, US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Nomura Phase4 Ventures, Delphi Ventures [d], Adams Street Partners, De Novo Ventures and Bay Partners.